BBIO - BridgeBio succeeds in late-stage encaleret study
2025-10-29 10:05:22 ET
More on BridgeBio Pharma
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript
- BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 - Slideshow
- BridgeBio Pharma, Inc. (BBIO) Presents at HFSA 2025 - Slideshow
- BridgeBio Pharma Q3 2025 Earnings Preview
- BridgeBio rises after late-stage muscular dystrophy trial success